3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
5
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Disease Progression
2
Triple Negative Breast Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Interventions
Lenalidomide
3
capivasertib
2
Bortezomib
2
tivozanib
1
Zoledronic Acid
1
Vitamin D
1
Temozolomide
1
Radiotherapy
1
Nivolumab
1
Gemcitabine
1
Fulvestrant
1
Etoposide
1
Dexamethasone
1
Cisplatin
1
Carboplatin
1
Calcium Dobesilate
1
Calcium
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Disease Progression
×
capivasertib
×
Clear all
NCT06635447
2026-03-27
CAPItrue
AstraZeneca
Phase 3
Active not recruiting
258 enrolled
NCT07281833
2026-02-27
CAPIcorn
West German Study Group
Phase 3
Recruiting
250 enrolled